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Abstract
Background: Verbal autopsy is an increasingly important methodology for assigning causes to otherwise
uncertified deaths, which amount to around 50% of global mortality and cause much uncertainty for health
planning. The World Health Organization sets international standards for the structure of verbal autopsy interviews
and for cause categories that can reasonably be derived from verbal autopsy data. In addition, computer models
are needed to efficiently process large quantities of verbal autopsy interviews to assign causes of death in a
standardised manner. Here, we present the InterVA-5 model, developed to align with the WHO-2016 verbal autopsy
standard. This is a harmonising model that can process input data from WHO-2016, as well as earlier WHO-2012
and Tariff-2 formats, to generate standardised cause-specific mortality profiles for diverse contexts.
The software development involved building on the earlier InterVA-4 model, and the expanded knowledge base
required for InterVA-5 was informed by analyses from a training dataset drawn from the Population Health Metrics
Research Collaboration verbal autopsy reference dataset, as well as expert input.
Results: The new model was evaluated against a test dataset of 6130 cases from the Population Health Metrics
Research Collaboration and 4009 cases from the Afghanistan National Mortality Survey dataset. Both of these
sources contained around three quarters of the input items from the WHO-2016, WHO-2012 and Tariff-2 formats.
Cause-specific mortality fractions across all applicable WHO cause categories were compared between causes
assigned in participating tertiary hospitals and InterVA-5 in the test dataset, with concordance correlation
coefficients of 0.92 for children and 0.86 for adults.
The InterVA-5 model’s capacity to handle different input formats was evaluated in the Afghanistan dataset, with
concordance correlation coefficients of 0.97 and 0.96 between the WHO-2016 and the WHO-2012 format for
children and adults respectively, and 0.92 and 0.87 between the WHO-2016 and the Tariff-2 format respectively.
Conclusions: Despite the inherent difficulties of determining “truth” in assigning cause of death, these findings
suggest that the InterVA-5 model performs well and succeeds in harmonising across a range of input formats. As
more primary data collected under WHO-2016 become available, it is likely that InterVA-5 will undergo minor re-
versioning in the light of practical experience. The model is an important resource for measuring and evaluating
cause-specific mortality globally.
Keywords: Verbal autopsy, Mortality surveillance, Civil registration, InterVA, Cause of death, World Health
Organization
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Background
The quality and performance of national health informa-
tion systems varies widely around the world, correlated
strongly with economic and infrastructural development.
Countries that currently operate efficient and detailed
health information systems, based on complete individual
data, typically started from nothing 200 to 300 years ago,
and began with basic registration of deaths and their
causes. If the major causes of death in a population can be
characterised, this leads to considerable insights in terms
of health priorities and the implementation of appropriate
interventions and services. However, the World Health
Organization (WHO) estimated that around 50% of 56
million deaths worldwide in 2015 were not registered with
information on cause [1]. Therefore, there is a great need
for cost-effective, rapid and consistent tools to address this
gap in the medium term.
Verbal autopsy (VA) has become an increasingly im-
portant approach for documenting deaths that other-
wise pass without registration or certification, typically
in lower-income countries and particularly in Africa
and Asia. The basic principle of VA is that a standardised
interview is conducted with family members or others
having detailed knowledge of the circumstances, signs and
symptoms leading to the death, and the interview data are
processed into likely medical causes of death.
Necessary tools for large-scale implementation of VA
comprise several essential components, which can be
used in conjunction with each other to achieve the
over-arching objective of making step-changes in the
proportion of deaths worldwide that are appropriately
registered by cause. Part of WHO’s normative global role
is to develop and update standard protocols for VA inter-
views and cause of death reporting categories, of which
the most recent version is the WHO 2016 verbal autopsy
instrument (WHO-2016) [2]. This new standard, taken as
a given starting point for developing InterVA-5, was pri-
marily intended to achieve harmonisation between earlier
WHO standards and the Tariff-2 system [3], which inevit-
ably led to a larger number of interview items.
Additionally, because VA interviews typically involve
multiple complex skip patterns (for example where par-
ticular interview items relate to specific age/sex groups),
there are considerable efficiency gains to be made by
handling VA interviews with portable data capture tools,
typically implemented on smartphones or tablets. This has
previously been shown to be an effective, cost-effective
and acceptable approach [4]. However, the InterVA-5
software does not provide data capture functions but is
designed to post-process VA interview data gathered by
various means.
Although physicians have been widely used to assign
individual causes of death using VA data after interviews
have been conducted, that approach can be costly, slow
and not always consistent between practitioners and con-
texts [5]. Thus, it has become more common to apply
automated computerised models to VA data, which are
much cheaper, faster and more consistent. It can be argued
that physicians may be able to bring additional nuances to
assigning causes to individual cases compared with auto-
mated models, particularly in specific research settings.
Additionally, careful physician review may play a role in
quality control and VA model development. Nevertheless,
making any significant future impact on categorising the
over 20 million uncertified deaths every year using VA will
necessarily depend on using automated methods.
There are currently three families of automated VA
models of relevance to the WHO-2016 standard, namely
InterVA, InSilicoVA and Tariff [3, 6, 7]. Initial work on
InterVA models dates from 2003 [8] and has passed
through a number of iterations since. InSilicoVA built
on the foundations of InterVA, aiming to achieve higher
precision and measures of uncertainty by, among other
things, simultaneously estimating distributions of individ-
ual cause-assignment probabilities and cause-specific mor-
tality fractions, and differentiating between negative and
unknown responses to VA responses. InSilicoVA is closely
related to InterVA, using the same probability base to re-
late indicators and causes, and thus uses the same inter-
view items. Tariff was first proposed in 2011 [9] and has
subsequently been revised and shortened to Tariff-2, as
implemented in the SmartVA-Analyze software [10].
Thus the aim of this paper is to present the development
and evaluation of InterVA-5, the latest product in the
InterVA family, designed to correspond to the WHO-2016
standard [11]. This builds substantially on the InterVA-4
model [6], which corresponded to the WHO 2012 verbal
autopsy instrument (WHO-2012), but InterVA-5 also
includes significant new concepts as well as updates
based on the experience of processing hundreds of
thousands of VA cases using InterVA-4. The harmonis-
ing concept behind WHO-2016 was carried forward
into the design of InterVA-5, which not only directly
corresponds to WHO-2016 but also incorporates back-
ward compatibility with WHO-2012 and InterVA-4 [6],
as well as coherence with Tariff-2 and the associated
SmartVA-Analyze model [10]. Since WHO-2012 and
Tariff-2 content are by definition separate subsets of
WHO-2016, it was feasible to design InterVA-5 as a
harmonising model that could handle WHO-2016,
WHO-2012 or Tariff-2 datasets, in the interests of achiev-
ing wider comparability and consistency in processing
existing data.
In addition, InterVA-5 incorporates a novel concept of
Circumstances Of Mortality CATegories (COMCAT) as
a tool that complements medical causes of death with
assigning circumstantial categories to deaths, related to
critical limiting factors for care seeking and utilisation
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processes at and around the time of death, as they occur
in any specific health systems and social context. For ex-
ample, for a woman whose medical cause of death is
assigned as obstetric haemorrhage, her death might have
occurred at home because she had no means or resources
to call for help or get to a health facility; another woman
with the same medical cause of death might have been in-
adequately managed during her delivery despite getting to
a health facility. The intention of COMCAT is to make
distinctions between important circumstances around a
death, particularly where these may not be reflected in
medical causes. The conceptual basis of COMCAT is
described elsewhere [12], and a detailed operational evalu-
ation of its implementation within InterVA-5 will follow
as a separate paper.
Implementation
The overall architecture of the InterVA-5 software fol-
lows the same general pattern as was implemented in
the InterVA-4 software [6], involving the following major
components:
1. System initiation—reading knowledge base and
accepting user input parameters
2. Reading input data file and checking format
3. Checking data consistency, excluding errors and
generating warnings
4. Processing likelihoods for each pregnancy status
category, for each case
5. Processing likelihoods for each cause of death
category, for each case
6. Processing likelihoods for each COMCAT, for
each case
7. Post-processing output file with pregnancy status,
up to three causes and COMCAT for each case
In line with the existing concept that InterVA products
are made available on an open-source basis, the InterVA-5
software is issued under the GNU General Public License
Version 3 (GPL3) and the accompanying knowledge base
that drives the system is also freely available. In the same
spirit, the specifications for the input and output files
are defined in non-proprietary comma-separated vari-
able (CSV) format. The executable software, code and
full user documentation are included in the download
(see linked GitHub repository) [11].
For historical reasons, the InterVA-5 software was first
implemented and compiled as a run-time version in
Microsoft Visual FoxPro 9.0, the same programming en-
vironment as has been used for earlier versions of
InterVA. In order to co-validate the software, a parallel
implementation in R was undertaken by a separate soft-
ware team at another institution, and test outputs from
the two separate implementations carefully checked for
any discrepancies or errors. The R implementation of
InterVA-5 is available via the openVA repository for
open-access VA resources as open source software under
GPL3 (see linked GitHub repository) [13]. The Windows
and R software versions are kept synchronised and pro-
duce the same results.
All of the InterVA family of models have used a simple
input format of binary questions. Up until InterVA-4,
the response of interest was always defined as “yes”, even
though that sometimes made the wording of questions
awkward. Therefore, InterVA-5 uses a data-driven concept
of a substantive response for each item, which may be “yes”
(e.g. “Did (s) he have a fever?”) or “no” (e.g. “Was the
placenta completely delivered?”), and the probabilistic mod-
elling updates likelihoods for each cause category on the
basis of substantive responses recorded in the VA data.
Where WHO VA items are specified in other ways
(e.g. as continuous variables for duration of symptoms),
InterVA takes pre-determined categories and imple-
ments each category as a binary variable. The detailed
specification of WHO-2016 [14] also includes a substan-
tial preamble of civil registration parameters which are
not intended to elucidate cause of death, such as civil iden-
tity numbers and residential addresses which are not rele-
vant to InterVA-5. Overall, the 305 items in WHO-2016
that are relevant to assigning cause of death correspond to
353 binary indicators in the InterVA-5 data input format,
plus an individual identifier field. InterVA-5 input data can
therefore be prepared from complete WHO-2016 data re-
cords, using a suitable script to convert to the 353 variables
plus identifier required in the CSV input file. Alternatively,
if there is a prior decision to use InterVA-5 as the inter-
pretation tool, a tablet data collection tool directly designed
for the InterVA-5 format can be implemented for the VA
interview and the data transferred directly (for example,
the MIVA utilities included in the linked GitHub reposi-
tory). Since WHO-2012/InterVA-4 and Tariff-2/Smart-
VA-Analyze are both subsets of the WHO-2016 standard
[2], it is also relatively straightforward to run conversion
scripts from those data formats to the InterVA-5 input for-
mat. Figure 1 shows the combinations of input indicators
for the three data formats (InterVA-5 353 indicators,
InterVA-4 245 and Tariff-2 241).
The established knowledge base that drove InterVA-4
(version 4.04) was used as the basis for the InterVA-5
knowledge base. As has always been the case with the
InterVA family of models, this knowledge base is an accu-
mulated resource, based on both such data sources as are
available plus syntheses of expert opinion, as previously
described [15]. To move from this InterVA-4 resource to a
revised version for InterVA-5, we needed to do four things:
1. Update with regard to changes in cause categories
between WHO-2012 and WHO-2016
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2. Update with regard to extra VA items in WHO-
2016 compared with WHO-2012
3. Update according to outstanding issues reported by
InterVA-4 users
4. Incorporate a knowledge base relating to the
COMCAT system
The only change in mortality cause categories moving
from WHO-2012 to WHO-2016 was a redefinition of the
WHO-2012 category 01.11 (haemorrhagic fever) into two
separate categories; 01.11 (haemorrhagic fever excluding
dengue fever) and 01.12 (dengue fever). Revised probabil-
ities for these two categories were reviewed and derived
on the basis of available evidence and expert input.
The additional items in WHO-2016 compared with
WHO-2012 were almost all contained in the Population
Health Metrics Research Consortium (PHMRC) refer-
ence dataset [16], which was a longer precursor of the
Tariff-2 format. Conditional probabilities for these items
were derived by randomly selecting half of the PHMRC
data as a training dataset and using that as a basis for
filling the probability base for the additional items. The
PHMRC reference dataset [16] was randomly divided
into equal train and test datasets for revising and testing
the InterVA-5 model. The training dataset was used pri-
marily to inform conditional probability assignments in
InterVA-5 for the 89 indicators (Fig. 1) present in the
Tariff-2 indicator subset but not in the WHO-2012 indi-
cator subset. The other half of the PHMRC dataset was
retained as a test dataset for the new model.
A few new or revised items (e.g. the new WHO-2016
item “Did (s) he receive (or need) antiretroviral therapy
(ART)?”, and splitting the InterVA-4 item “Did (s) he
have fever for less than 2 weeks before death?” into “Did
the fever last less than a week before death?” and “Did
the fever last at least one week, but less than 2 weeks be-
fore death?”, which was specifically relevant to the add-
itional WHO VA cause category for dengue fever)
required revisions to the knowledge base on the basis of
expert opinion. The complete conditional probability
matrix that InterVA-5 uses is included as a spreadsheet
in the download of the model [11].
A few reported issues with InterVA-4, such as im-
plausible over-attribution of WHO, cause category 06.01
(acute abdomen) and under-attribution of 04.01 (acute
cardiac), an incorrect balance between fresh and macer-
ated stillbirths (11.01 and 11.02) and over-attribution of
01.03 (HIV/AIDS related death) in young children were
addressed within the overall process of revising the
knowledge base.
Social scientists contributed to a process of estimating
conditional probabilities for the COMCAT factors, on
the same principles as the estimation of probabilities for
causes of death. This was an inherently different exercise
in that no data existed in absolute terms nor indeed any
sense that COMCAT outputs could be considered fun-
damentally correct or incorrect. This is an area that will
be revisited as experience of its use grows, but the
current InterVA-5 knowledge base constitutes a starting
point for this novel concept.
Thus, overall the implementation of InterVA-5 consti-
tutes a cause of death model which is fully compatible
with the WHO-2016 instrument, which can also process
WHO-2012 and Tariff-2 datasets, and which can assign
Fig. 1 Conceptual framework for the development and testing of the InterVA-5 model
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deaths to all 64 WHO-2016 cause of death categories.
The public-domain InterVA-5 model is available on an
open-source basis and on a typical personal computer
processes about 100 VA cases per minute.
Results
Testing the new InterVA-5 software has been an import-
ant part of the development process. As with any soft-
ware update, evaluating continuity with the previous
version is important, as well as overall performance of
the new version. Evaluating assignment of cause of death
in any context is notoriously difficult because of a lack
of any absolute comparator [17]. InterVA-4 has previ-
ously been extensively compared with the same PHMRC
dataset as used here [17], physician assigned causes of
death [18], co-validated with Global Burden of Disease
mortality estimates [19] and deployed in large-scale mor-
tality analyses [20]. For evaluating comparability between
different approaches to modelling the same set of VA
cases, the concordance correlation coefficient (CCC), as
implemented in the Stata concord command, is a useful
measure of equivalence.
Since the WHO-2016 instrument is relatively new,
there are not yet any extensive VA data sources specific-
ally collected under that protocol available for evalu-
ation. However, some earlier VA archives do contain
data including a substantial proportion of WHO-2016
items, which therefore for the present have to suffice as ma-
terial for evaluating InterVA-5. There are two major objec-
tives: firstly to compare the InterVA-5 cause of death
assignments with an established, best available, reference
source (even though no perfect reference source exists) and
secondly to compare the performance of InterVA-5 when
processing data aligned with WHO-2016, WHO-2012 and
Tariff-2 input formats.
Firstly, the 6130 VA records in the PHMRC test dataset
were used, which covered 248/353 (70.3%) of the InterVA-5
input indicators. The strengths of the PHMRC dataset are
that it includes causes of death attributed by tertiary hospi-
tals, though not all the WHO-2016 cause of death categor-
ies are included, and its verbal autopsy data were not used
as part of assigning the hospital causes of death. The
PHMRC dataset causes did not differentiate between fresh
and macerated stillbirths, nor between different haemor-
rhagic fevers, which were amalgamated into stillbirths and
haemorrhagic fevers for this comparison. Because the
hospital and VA processes leading to the attribution of in-
determinate cause to some deaths were very different, inde-
terminate outcomes (1.4% for hospital and 11.1% for VA)
were excluded by redistributing proportionally over all
other causes for this comparison. Cause-specific mortality
fractions (CSMFs) for WHO-2016 cause categories, from
the hospital causes and InterVA-5, are shown in Table 1,
for the 5-plus and under-5 age groups, by WHO-2016
cause categories and broad groups. InterVA-5 CSMFs were
derived by aggregating individually assigned likelihoods for
each cause, and dividing by total deaths. Figure 2 shows the
agreement between the two sources, for deaths under 5
years and those 5 years and older, with different colours
corresponding to the broad causes shown in Table 1. The
points near the axes reflect rare causes that were either un-
represented or not directly comparable between the two
sources, such as childhood cancers, amounting to 3.1% of
the total deaths under 5 years and 1.0% of those 5 years and
older. Nevertheless, we retained these points in the overall
comparisons so as to take a conservative approach to asses-
sing concordance. The CCC was 0.922 (95% CI 0.871 to
0.974) for the younger age group and 0.858 (95% CI 0.786
to 0.930) for the older age group.
For the second objective of testing the performance of
the new InterVA-5 software when confronted by different
subsets of input indicators, the Afghanistan 2010 national
mortality survey dataset [21] was used, being a national
all-age population-based dataset that was collected inde-
pendently of any of the WHO-2016, WHO-2012 or
Tariff-2 protocols, but included 257/353 (72.8%) of the
InterVA-5 items. When reduced to the InterVA-4 and
Tariff-2 subsets of the InterVA-5 items, 202/245 (82.4%)
and 188/241 (78.0%) respectively of those subsets were
available, as shown in Fig. 1. Table 2 shows the InterVA-5
outputs for the three datasets based on the WHO-2016,
WHO-2012 and Tariff-2 standards for the under-5 and
5-plus age groups, by WHO-2016 cause categories and
broad groups. Figure 3 shows the agreement between the
outputs using the InterVA-5 and InterVA-4 datasets, and
Fig. 4 the InterVA-5 and Tariff-2 datasets. CCCs for
InterVA-4 were 0.968 (95% CI 0.947 to 0.988) for the
under-5 age group, and 0.961 (95% CI 0.940 to 0.983) for
the 5-plus age group; for Tariff-2, the CCCs were 0.918
(95% CI 0.869 to 0.968) for the under-5 age group and
0.871 (95% CI 0.806 to 0.936) for the 5-plus age group.
Points near the axes in these comparisons reflect very rare
causes that were barely measurable from this dataset.
Finally, as with any software update, it is important to
demonstrate version continuity together with the effects of
intentional changes as part of the update process. Figure 5
shows the Afghanistan dataset as processed by InterVA-4
(version 4.04), compared with the new InterVA-5 software
processing the InterVA-4 subset of inputs. Excluding the
intentional changes (shown as diamond-shaped markers in
Fig. 5), CCC was 0.909 (95% CI 0.860 to 0.958).
Discussion
The development of the InterVA-5 model follows our
established practice of providing analytical models for
verbal autopsy data that correspond to international
WHO VA standards. WHO-2016 was specifically devel-
oped as a harmonisation of various existing VA standards,
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Table 1 Cause-specific mortality fractions (CSMFs) by age group
for 6130 deaths from the Population Health Metrics Research
Consortium (PHMRC) verbal autopsy reference dataset, with
PHMRC cause of death determined from clinical data at tertiary
hospitals involved in final care, and processed by the InterVA-5
model from PHMRC verbal autopsy data. Causes of death are
shown in WHO-2016 categories, as well as in broad groups
WHO-2016 cause category CSMF % ≥ 5
years
CSMF % < 5
years
PHMRC InterVA-5 PHMRC InterVA-5
01.01 Sepsis (non-obstetric) 0.22 0.17 2.68 1.13
01.02 Acute resp infect incl
pneumonia
7.00 7.23 12.93 13.72
01.03 HIV/AIDS related death 6.06 7.70 0.42 0.84
01.04 Diarrhoeal diseases 3.09 2.63 5.52 9.27
01.05 Malaria 1.40 0.46 2.79 1.58
01.06 Measles 0.12 0 0.21 0.05
01.07 Meningitis and
encephalitis
0.24 0.57 1.95 3.03
01.08 & 10.05 Tetanus 0 0.11
01.09 Pulmonary tuberculosis 3.16 6.52 0.16 0.00
01.10 Pertussis 0 0.27
01.11 Haemorrhagic fever 0.34 0.14 0.89 0.31
01.99 Other and unspecified
infect dis
3.31 3.30 0.74 1.10
02.01 Oral neoplasms 0.29 0.07
02.02 Digestive neoplasms 2.73 5.14
02.03 Respiratory neoplasms 1.40 1.38
02.04 Breast neoplasms 2.27 1.40
02.05 & 02.06 Reproductive
neoplasms m&f
2.78 2.87
02.99 Other and unspecified
neoplasms
3.41 0.83 0.26 0.00
03.02 Severe malnutrition 0 0.30 0 2.00
03.03 Diabetes mellitus 5.14 4.12 0 0.11
04.01 Acute cardiac disease 5.12 6.13
04.02 Stroke 7.37 10.27
04.03 Sickle cell with crisis 0 0.08 0 0.50
04.99 Other and unspecified
cardiac dis
5.19 6.10 1.63 0.09
05.01 Chronic obstructive
pulmonary dis
1.98 0.61
05.02 Asthma 0.65 0.04
06.01 Acute abdomen 0 0.68 0 0.20
06.02 Liver cirrhosis 3.74 3.86
07.01 Renal failure 4.81 3.13
08.01 Epilepsy 0.39 0.39 0 0.18
09.01 Ectopic pregnancy 0 0.08
09.02 Abortion-related death 0 1.78
09.03 Pregnancy-induced
hypertension
1.50 1.21
Table 1 Cause-specific mortality fractions (CSMFs) by age group
for 6130 deaths from the Population Health Metrics Research
Consortium (PHMRC) verbal autopsy reference dataset, with
PHMRC cause of death determined from clinical data at tertiary
hospitals involved in final care, and processed by the InterVA-5
model from PHMRC verbal autopsy data. Causes of death are
shown in WHO-2016 categories, as well as in broad groups
(Continued)
WHO-2016 cause category CSMF % ≥ 5
years
CSMF % < 5
years
PHMRC InterVA-5 PHMRC InterVA-5
09.04 Obstetric haemorrhage 1.55 1.07
09.05 Obstructed labour 0.27 0
09.06 Pregnancy-related sepsis 0.75 0.14
09.07 Anaemia of pregnancy 0.70 0
09.08 Ruptured uterus 0 0.02
09.99 Other and unspecified
maternal CoD
1.04 0.27
10.01 Prematurity 8.41 15.81
10.02 Birth asphyxia 14.41 8.02
10.03 Neonatal pneumonia 5.05 1.77
10.04 Neonatal sepsis 5.57 2.10
10.06 Congenital malformation 6.31 8.93
10.99 Other and unspecified
neonatal CoD
0 0.11
11.99 Stillbirth 25.24 25.47
12.01 Road traffic accident 3.41 4.18 0.58 0.78
12.03 Accidental fall 2.27 1.52 0.47 0.44
12.04 Accidental drowning
and submersion
1.76 0.82 0.53 0.46
12.05 Accidental exposure
to smoke fire & flame
1.84 1.21 1.00 0.64
12.06 Contact with venomous
plant/animal
1.23 0.84 0.32 0.23
12.07 Accidental poisoning
& noxious substances
1.16 0.12 0.21 0.17
12.08 Intentional self-harm 1.69 3.61
12.09 Assault 2.61 4.06 0.37 0.56
12.99 Other and unspecified
external CoD
1.16 0.05 0 0.02
98 Other and unspecified NCD 4.86 2.89 1.37 0
Broad groups
Infections 21.63 28.72 28.29 31.41
Neoplasms 12.88 11.69 0.26 0
Cardiovascular diseases 17.68 22.58 1.63 0.59
Other non-communicable
diseases
24.87 16.03 26.59 27.96
Maternal and neonatal
causes
5.81 4.57 39.75 36.74
Stillbirths 25.24 25.47
External causes 17.13 16.41 3.48 3.30
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and accordingly InterVA-5 was specifically developed to
be, as far as technically possible, a unifying and updated
model capable of handling a range of input formats corre-
sponding to various VA standards. One might expect that
InterVA-5 would perform most robustly when used with
data meeting the full WHO-2016 specification, therefore
having the maximum amount of information available.
However, it is important, as demonstrated here, that it can
also perform reasonably comparably with WHO-2012 and
Tariff-2 input formats, even though those do not fully
meet current standards. Tracking mortality patterns con-
sistently over time and place is critical in terms of evaluat-
ing health and development policy and therefore the
ability to process earlier VA data collected under previous
standards is strategically important.
The absolute accuracy of VA in general, and in asses-
sing specific models for assigning cause of death from
VA data, raises difficult questions which have been ex-
tensively explored in various settings. In many ways, the
performance of VA methods has received more scientific
scrutiny than the sometimes serendipitous nature of in-
dividual physicians’ certification of deaths. There is no
process for cause of death attribution leads to absolute
“truth” for every case, and the lack of precise compara-
tors often makes assessments of various VA methods
contentious. Here we have made use of the interesting,
though by no means perfect, PHMRC reference dataset
[16]. This at least provides cause of death as clinically
assigned by the tertiary facilities in which the deaths oc-
curred, which was backed up by laboratory and diagnos-
tic evidence. Nevertheless, one can find cases where
correspondence between the clinical cause of death and
responses to questions in the VA interview was not obvi-
ously congruent. However, as evident in Fig. 2, the over-
all similar patterns of mortality between InterVA-5 and
the PHMRC data, albeit in a tertiary hospital population
unrepresentative of more usual VA applications, are an
encouraging starting point. The comparison of broad
cause categories presented at the end of Table 1 also
suggests that at an overall level there are not major dif-
ferences that would give rise to public health concerns.
Earlier versions of InterVA models have been used ex-
tensively and have been seen to deliver largely plausible
findings over a wide range of settings and mortality pat-
terns [20]. Nevertheless, as with any modelling exercise,
there are always possibilities for improvement, with the
caveat that a so-called improvement in one respect must
not lead to deterioration in other respects. Our detailed
evaluations reported here, using the Afghan VA dataset,
of the new InterVA-5 model in relation to its anteced-
ents are therefore very important. Although it may be
difficult to compare performance on very rare causes of
death, Figs. 3, 4 and 5 clearly demonstrate that on a
population basis there is strong overall consistency be-
tween InterVA-5 and earlier models and standards.
Demonstrating this continuity between models is im-
portant for long-term studies of population mortality.
As yet, very few primary data have been collected
under the WHO-2016 standard, which limits the field
applications of InterVA-5 to date, and hence the source
material for evaluating InterVA-5. As was the case with
InterVA-4, which underwent a series of minor modifica-
tions in response to feedback, issued as new versions of
the public software over the past 5 years, it is anticipated
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Fig. 2 Cause-specific mortality fractions (CSMFs) by age group for 6130 deaths from the Population Health Metrics Research Consortium (PHMRC)
verbal autopsy reference dataset, with PHMRC cause of death determined from clinical data at tertiary hospitals involved in final care, and
processed by the InterVA-5 model from PHMRC verbal autopsy data, against the line of equivalence
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Table 2 Cause-specific mortality fractions (CSMFs) by age group for 4009 deaths from the Afghanistan Mortality Survey verbal
autopsy dataset, with cause of death determined by the InterVA-5 model using datasets extracted on the basis of WHO-2016, WHO-
2012 and Tariff-2 indicator formats. Causes of death are shown in WHO-2016 categories, as well as in broad groups
WHO-2016 cause category CSMF % ≥ 5 years CSMF % < 5 years
WHO-2016 WHO-2012 Tariff-2 WHO-2016 WHO-2012 Tariff-2
01.01 Sepsis (non-obstetric) 0.02 0.04 0.18 0.64 0.32 1.21
01.02 Acute resp infect incl pneumonia 2.20 3.24 3.52 12.24 14.27 12.68
01.03 HIV/AIDS related death 0.75 1.02 0 0.33 0.10 0.10
01.04 Diarrhoeal diseases 2.80 3.08 0.59 14.25 10.91 6.92
01.05 Malaria 0.05 0.30 0 0.03 0.18 0
01.06 Measles 0.05 0 0 0.17 0.05 0.07
01.07 Meningitis and encephalitis 1.26 1.46 1.49 2.06 2.52 2.30
01.08 Tetanus 0 0.05 0
01.09 Pulmonary tuberculosis 10.62 12.37 6.97 0.15 0.15 0.13
01.10 Pertussis 0.35 0.05 0.78
01.11 Haemorrhagic fever (non-dengue) 0.23 0.04 0 0 0 0.05
01.12 Dengue fever 0.09 0 0.20
01.99 Other and unspecified infectious disease 0.82 0.50 0.66 0.28 0.14 1.41
02.01 Oral neoplasms 0.35 0.69 0.34
02.02 Digestive neoplasms 8.24 7.37 9.74
02.03 Respiratory neoplasms 4.15 4.49 1.97
02.04 Breast neoplasms 0.96 0.96 0.37
02.05 & 02.06 Reproductive neoplasms m&f 0.68 0.91 0.56
02.99 Other and unspecified neoplasms 5.96 4.25 2.88 0.10 0 0.20
03.01 Severe anaemia 0.08 0.18 0.03 0 0 0.04
03.02 Severe malnutrition 2.20 4.08 0.23 5.92 8.21 2.54
03.03 Diabetes mellitus 1.45 1.85 4.07 0.05 0 0.39
04.01 Acute cardiac disease 4.73 2.24 5.24
04.02 Stroke 7.25 6.00 3.73 0 0 0.03
04.99 Other and unspecified cardiac disease 5.67 3.71 5.75 0 0 0.12
05.01 Chronic obstructive pulmonary disease 0.97 1.58 1.24
05.02 Asthma 0.39 0.65 0.60 0 0 0.05
06.01 Acute abdomen 0.39 1.84 1.65 0.05 0.13 1.34
06.02 Liver cirrhosis 1.58 1.02 4.70 0 0.09 2.12
07.01 Renal failure 0.74 0.33 2.16 0 0 0.17
08.01 Epilepsy 0.41 0.50 0.64 0.10 0.10 0.81
09.02 Abortion-related death 0.05 0 0.27
09.03 Pregnancy-induced hypertension 0.99 0.99 0.31
09.04 Obstetric haemorrhage 1.73 1.73 2.10
09.05 Obstructed labour 0 0.03 0
09.06 Pregnancy-related sepsis 0.04 0.09 0.08
09.07 Anaemia of pregnancy 0 0 0.11
09.08 Ruptured uterus 0.08 0.05 0.48
09.99 Other and unspecified maternal cause 0 0 0.14
10.01 Prematurity 6.99 3.31 6.85
10.02 Birth asphyxia 9.22 9.43 5.25
10.03 Neonatal pneumonia 4.81 6.55 6.82
10.04 Neonatal sepsis 1.36 2.15 1.07
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Table 2 Cause-specific mortality fractions (CSMFs) by age group for 4009 deaths from the Afghanistan Mortality Survey verbal
autopsy dataset, with cause of death determined by the InterVA-5 model using datasets extracted on the basis of WHO-2016, WHO-
2012 and Tariff-2 indicator formats. Causes of death are shown in WHO-2016 categories, as well as in broad groups (Continued)
WHO-2016 cause category CSMF % ≥ 5 years CSMF % < 5 years
WHO-2016 WHO-2012 Tariff-2 WHO-2016 WHO-2012 Tariff-2
10.06 Congenital malformation 3.48 3.31 3.43
10.99 Other and unspecified neonatal cause 1.10 2.79 1.83
11.01 Fresh stillbirth 18.27 19.71 16.91
11.02 Macerated stillbirth 3.58 4.05 4.05
12.01 Road traffic accident 7.13 5.07 5.21 0.66 0.66 0.65
12.03 Accidental fall 1.48 0.84 0.88 0.58 0.49 0.60
12.04 Accidental drowning and submersion 1.01 0.79 0.79 0.67 0.67 0.70
12.05 Accidental exposure to smoke fire & flame 0.44 0.38 0.35 0.35 0.30 0.35
12.06 Contact with venomous plant/animal 0.14 0.14 0.14 0.36 0.41 0.41
12.07 Accidental poisoning & noxious substances 0.13 0.12 0.06 0 0.08 0
12.08 Intentional self-harm 0.77 0.77 0.41
12.09 Assault 4.99 5.78 4.86 0.05 0.05 0.05
12.99 Other and unspecified external cause 0.26 0.25 0.15 0.15 0.10 0.10
98 Other and unspecified NCD 1.17 1.51 1.78 0 0 0.04
99 Indeterminate 14.60 16.70 22.57 11.56 8.71 17.23
Broad groups
Infections 18.80 22.10 13.41 30.59 28.69 25.85
Neoplasms 20.34 18.67 15.86 0.10 0 0.20
Cardiovascular diseases 17.65 11.95 14.72 0 0 0.15
Other non-communicable diseases 9.37 13.55 17.10 6.12 8.54 7.50
Maternal and neonatal causes 2.89 2.89 3.49 26.96 27.54 25.25
Stillbirths 21.85 23.76 20.96
External causes 16.35 14.14 12.85 2.82 2.76 2.86
Indeterminate 14.60 16.70 22.57 11.56 8.71 17.23
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Fig. 3 Cause-specific mortality fractions (CSMFs) by age group for 4009 deaths from the Afghanistan Mortality Survey verbal autopsy dataset, with
cause of death determined by the InterVA-5 model using WHO-2016 and WHO-2012 input datasets, against the line of equivalence
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that InterVA-5 will experience a similar software life
cycle as experience of its use extends. We therefore par-
ticularly welcome feedback from InterVA-5 users.
Conclusions
At present, InterVA-5 and the related InSilico model
are the only tools for analysing VA data which are fully
compatible with the WHO-2016 standard (in terms of
VA interview input items and deriving all of the
WHO-VA cause of death categories as outputs). The
InterVA-5 model brings the additional advantage of
being able to handle data from the earlier WHO-2012
and Tariff-2 standards reasonably well, thus bringing a
helpful degree of harmonisation across the interpret-
ation of various VA data formats. This harmonisation is
important for monitoring long-term trends over periods
when different VA standards have been used. As with any
VA model, the usefulness of the outputs depends on using
good quality source material from VA interviews, carefully
preparing input data, and appropriately processing and
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Fig. 4 Cause-specific mortality fractions (CSMFs) by age group for 4009 deaths from the Afghanistan Mortality Survey verbal autopsy dataset, with
cause of death determined by the InterVA-5 model using WHO-2016 and Tariff-2 input datasets, against the line of equivalence
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interpreting outputs. It is likely that widespread use of the
model will lead to future minor refinements. The free
availability of InterVA-5 means that large quantities of VA
data, even into the millions of cases which could be
generated in national civil registration processes, can now
be processed cheaply, feasibly and consistently. Current
measurement needs for the United Nations’ Sustain-
able Development Goals, as well as monitoring and
evaluating progress towards WHO’s visions for Uni-
versal Health Care and non-communicable disease
control, make standardised cause-specific mortality meas-
urement techniques, as implemented in InterVA-5, an es-
sential part of the global toolkit [22]. In addition,
InterVA-5 is a tool that can readily be used by national or
regional health services to track local mortality patterns.
Availability and requirements
Project name: InterVA-5
Project home page: www.interva.net
Operating system(s): runs in a DOS window on a
personal computer; platform independent
Programming language: FoxPro (compiled into a run-
time format)
Other requirements: runs directly from the folder into
which it is downloaded
Licence: GNU General Public Licence Version 3
Any restrictions to use by non-academics: none
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Mortality CATegories; CSMF: Cause-specific mortality fraction; CSV: Comma-
separated variable; PHMRC: Population Health Metrics Research Consortium;
VA: Verbal autopsy; WHO: World Health Organization; WHO-2012: World
Health Organization 2012 verbal autopsy standard; WHO-2016: World Health
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